9:00 am
Check-in
10:00 am
Welcome
10:15 am
Session I
Chairs: Ulrike Köhl (Fraunhofer IZI / University Medicine Leipzig, Germany) & Florian Lordick (University Medicine Leipzig, Germany)
Navigating the bridge from lab to clinic in stem cell-based therapies
Keynote
Thomas Hassing Ronøe Carlsen (Novo Nordisk Foundation Cellerator, Denmark)
Optimising efficacy of tumor-specific T cells and manufacturing scalability
Keynote
Felix Lorenz (Captain T Cell, Germany)
Engineering persistence in off-the-shelf cell therapies
Keynote
Karl-Johan Malmberg (University of Oslo, Norway)
11:45 am
Break
12:00 pm
Industry symposium
Supported by AstraZeneca GmbH
The evolving CAR-T landscape in multiple myeloma: Advances in design, targeting, and manufacturing
Johannes Waldschmidt (Charité – Universitätsmedizin Berlin, Germany)
Michael Hudecek (University Hospital Würzburg, Germany)
12:45 pm
Break
1:30 pm
Industry symposium – Immune modulating therapies in oncology: From bench to bedside
Supported by J&J Innovative Medicine Janssen-Cilag GmbH
Chair: Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany)
Next steps of cell- and antibody-based therapy from an industry perspective: Advances in (immune) oncology of Johnson & Johnson
Ralf Angermund (J&J Innovative Medicine, Germany)
CAR-T cell therapy – Translating science into clinical practice
Vladan Vucinic (University Medicine Leipzig, Germany)
Discussion and future perspectives
Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany)
2:15 pm
Break
2:30 pm
Session II
Chairs: Zoltan Ivics (Fraunhofer IZI, Germany) & Claire Fabian (Fraunhofer IZI, Germany)
Reprogramming the tumor microenvironment toward immune activation by targeted gene-based cytokine delivery
Keynote
Luigi Naldini (Vita-Salute San Raffaele University, Italy)
Fantastic parvoviral gene therapy vectors and how to find them
Keynote
Dirk Grimm (University of Heidelberg, Germany)
Flash Talk
Minicircle DNA for virus-free engineering of gene-modified cells
Marcello Stein (PlasmidFactory GmbH, Germany)
Supported by PlasmidFactory GmbH
Inducing immunogenic lymphoid niches across cancers by tumor-to-dendritic cell reprogramming
Gaia Fontanari (Lund University, Sweden)
4:00 pm
Poster session I
PP01 – Endoplasmic reticulum stress modulation reshapes the tumor immune microenvironment and enhances dendritic cell vaccine efficacy in ovarian cancer
Barbora Vavrušáková (Czech Republic)
PP03 – Advancements in automated TIL manufacturing: Clinical-scale pre-REP and REP using CliniMACS Prodigy®
Julia Atanasov (Germany)
PP05 – Morphomechanical phenotyping of human immune cells by high-throughput deformability cytometry (DC)
Jessica Freitag (Germany)
PP07 – Assessing TCR T cell therapies for solid tumors using 3D bioprints
Xu Holtkotte (Germany)
PP09 – Evolution of CD4‑specific CAR constructs towards clinical application in NK cell therapies
Leonhard Schlosser (Germany)
PP11 – Identification of vector integration sites in Cilta-Cel-treated multiple myeloma patients
Conny Blumert (Germany)
PP13 – Multimodal profiling reveals actionable vulnerabilities in CAR T-derived T-cell lymphoma
Christina Kuhn (Germany)
PP15 – BioThrust bioreactor technology for scalable production of allogeneic NK cell therapeutics
Kristina Roth (Germany)
PP17 – Exploring low-energy electron irradiation as an alternative to extracorporeal photopheresis for GvHD treatment
Maria Schricker (Germany)
PP19 – CD19- and CD20-directed NKG2D bispecific antibodies to restore the NKG2D axis and to potently activate NK cells against leukemia cells
Katja Klausz (Germany)
PP21 – Increasing filling precision: Advances in the CliniMACS Prodigy® TCTf process
Bianca Weidemann (Germany)
PP25 – Next-generation CLEC12A-CAR-NK cells combining a novel VHH binding domain and KLRC1 disruption for AML immunotherapy
Janika Sosat (Germany)
PP27 – T2EVOLVE Association: A sustainable European ecosystem for innovation and access in cell-based therapies
Carmen Sanges (Germany)
PP29 – A single-cell, droplet-based assay for CAR-T potency profiling: Effector and target cell viability and cell-cell contact kinetics on the Envisia platform
Clare Szybut (UK)
PP31 – Microbial metabolite-guided CAR T-cell engineering enhances anti-tumor immunity
Maik Luu (Germany)
PP33 – Targeting the molecular mimicry induced by sialyl transferase-expressing C. jejuni strains during Guillain-Barré syndrome by tailor-made cellular immunotherapies
Sandra Freier (Germany)
PP35 – Scalable hollow-fiber impeller bioreactor for primary T cell expansion: Evaluation of fed-batch and perfusion modes
Felipe Veliz Valenzuela (Germany)
PP37 – Towards a universal lipid nanoparticle (LNP) platform for multiplex engineering of next- generation ex vivo cell therapies
Martin Rabel (Canada)
PP39 – Synthetic Transposons for Individualised Cell and Gene Therapies
Chris Lamprecht (Germany)
PP41 – Development of a TCR-like CAR with enhanced antigen sensitivity to improve CAR T cell therapy against solid tumors
Juliane Kliehm (Germany)
PP45 – Scalable iPSC manufacturing and differentiation using innovative membrane-stirrer bioreactors: from high-density expansion to functional cell therapies
Marco Oliveira (Germany)
PP47 – EGFR-targeting CAR-NK92 cells engage prostate cancer spheroids
Mina Abroudi (Finland)
PP49 – Modulation of CAR T cell immunoreactivity using MAX.16H5 antibody incubation for the generation of immunotolerant allogeneic CAR T cells
Nadine Heimer (Germany)
PP51 – Mechanistic modeling of anti-BCMA CAR-T cell dynamics in relapsed and refractory multiple myeloma
Yuri Garcia Vilela (Germany)
5:00 pm
Session III
Chairs: Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany) & Sandy Tretbar (Fraunhofer IZI, Germany)
From science to scale: Lessons in cell therapy development
Keynote
Angela Vollstedt (Novartis, Austria)
The evolving field of cellular therapy in LBCL
Keynote
Anna Sureda (Catalan Institute of Oncology, Spain)
Longitudinal tracing of long-term persisting CAR T cells following ciltacabtagene autoleucel treatment in patients with multiple myeloma
Michael Rade (Fraunhofer IZI, Germany)
Development of novel CAR cell therapeutics in pediatric AML
Sabrina Schuster (Goethe-University Frankfurt, Germany)
6:30 pm
Get-together
8:15 pm
Check-in
9:00 am
Session IV
Chair: Dominik Schmiedel (Fraunhofer IZI, Germany) & Katharina Schindler-Wnek (Fraunhofer IZI, Germany)
Fraunhofer IZI – Accelerating innovation in cell and gene therapy: Research-driven solutions from process development to manufacturing
Anna Dünkel (Fraunhofer IZI, Germany)
Flash Talk
Understanding the barriers of CAR-T therapy and development towards point-of-care operational models
Dominik Griebling (Fresenius, Germany)
Supported by Fresenius SE & Co. KGaA
Clinical and manufacturing advances in allogeneic NK and CAR-NK cell therapy: From MRD-positive AML to autoimmune disease
Jan Spanholtz (Glycostem Therapeutics, The Netherlands)
9:45 am
Break
10:00 am
Session V
Chairs: Florian Lordick (University Medicine Leipzig, Germany) & Ulrich Hacker (University Medicine Leipzig, Germany)
Role of microbiome for response to chemotherapy and immunotherapy in gastrointestinal cancers
Keynote
Joseph Tintelnot (Universitätsklinikum Hamburg-Eppendorf, Germany)
Due to a short-term change, this presentation will be given by Irena Beidler (Universitätsklinikum Hamburg-Eppendorf, Germany).
Decoding MSI cancers: From the immune microenvironment to response and resistance to immunotherapy
Keynote
Florence Renaud (Sorbonne University, France)
Loss of LEDGF/p75 disrupts DNA damage signaling and sensitizes patient-derived colorectal cancer cells to 5-fluorouracil
Victoria Liedtke (Brandenburg University of Technology Cottbus-Senftenberg, Germany)
Functional MMR empowers efficient cDC1 reprogramming in MSS colorectal cancer
Sandra Schwarz (University Medical Center Rostock, Germany)
11:30 am
Break
11:45 am
Industry symposium – Advancing hematology: Current therapies in MDS and the future in multiple myeloma
Supported by Bristol Myers Squibb GmbH & Co. KGaA
Chair: Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany)
Treatment update in lower-risk MDS
Kathrin Rieger (Charité – Universitätsmedizin Berlin, Germany)
CELMoDs in multiple myeloma – Mezigdomide data deep dive
David Böckle (Charité – Universitätsmedizin Berlin, Germany)
12:30 pm
Break
1:15 pm
Poster session II
PP02 – Development of CAR NK cell therapy inspired by mechanistic study of immune evasion in solid tumors
Manasa Srinivasan (India)
PP04 – Leaving SB100X behind – Development of a new hyperactive Sleeping Beauty transposase for cell engineering
Natalie Forkert (Germany)
PP06 – Investigating small molecule modulators of temozolomide and thymidine toxicity in glioblastoma multiforme
Manasvini Sridharr (Germany)
PP08 – Volatilomic and biomechanical analysis as windows into immune cell function
Emilia Flores Naranjo (Germany)
PP10 – CAR FINDER: Revolutionizing CAR T cells
Robert Serfling (Germany)
PP12 – Establishment of a cell line based antibodydependent cellular phagocytosis (ADCP) assay, using frozen assay ready cells
Felix Hackstein (Germany)
PP14 – Bridging the gap: Developing bispecific antibodies as adaptor molecules for LNP-mediated in vivo CAR T cell engineering in AML
Ela Çetin (Germany)
PP16 – Humanized mouse models for the preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers – Enhanced in vivo and ex vivo analysis enables deeper characterization
Maria Stecklum (Germany)
PP18 – Targeting B cell neoplasia with NKp30-directed bispecific natural killer cell engagers
Dorothee Winterberg (Germany)
PP20 – Lipid nanoparticle-mediated mRNA delivery for ex vivo engineering of CD123-specific CAR NK cells
Nadine von Auw (Germany)
PP22 – Development of a cost-effective allogenic macrophage cell therapy against solid tumors
Jessica Nitsche (Germany)
PP24 – Dual nanobody-CAR-NK cells facilitate versatile „OR-Gated“ killing to mitigate antigen escape in AML
Kamala Bharathi Ramalingam (Germany)
PP26 – Spatial biodistribution analysis of in vivo generated CAR T cells using MICS technology
Juliane Schwarzer (Germany)
PP28 – Establishment of an in vitro epithelial-endothelial co-culture barrier model to investigate CAR-T-cell-interactions with physiological barriers
Charlotte Schwister (Germany)
PP30 – LipiGo enables extrahepatic RNA delivery as a foundation for in vivo immune-cell engineering
Ceren Kimna (Germany)
PP32 – Operational barriers drive access limitations to CAR-T cell therapy in Germany: Results from the EASYGEN multicenter survey
Dominik Griebling (Germany)
PP34 – The transmembrane adaptors SIT and TRIM as tunable negative regulators of T cell activation and checkpoint balance
Nouria Jantz-Naeem (Germany)
PP36 – Metformin alleviates CD8+ T cell exhaustion induced by cancer-conditioned adipose-derived mesenchymal stromal cells in association with reduced mitochondrial hyperpolarization
Chau Ton Nu (South Korea)
PP38 – Epstein–Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways
Alina Steffens (Germany)
PP40 – Proximity network assay (PNA) technology, decodes the membrane architecture of CAR T cells during tumor interaction
Hanna van Ooijen (Sweden)
PP42 – Tyrosine kinase inhibitors as sensitisers for CAR T-cell therapy in solid tumour
Dmitry Chernyakov (Germany)
PP44 – Reducing barriers to pediatric CAR-T therapy: A simplified and efficient anti-CD19 CAR-T cell production using the G-Rex system
Aesha Ali (Qatar)
PP46 – VivoCell: An open-access precision delivery platform for in vivo CAR T cell engineering
Devin Stranford (USA)
PP48 – Systematic cytokine screen identifies dual IL-2/IL-21 armoring as a potent NK cell strategy against high-risk AML
Sebastian John (Germany)
PP50 – A novel cell surface protein interactome approach to immune synapse reorganization after bispecific antibody therapy
Christina Kuhn (Germany)
PP52 – mRNA-delivered mutant IL-2 preferentially expands mutant IL-2Rα-engineered T cells for enhanced solid-tumor control
Matthias Birtel (Germany)
2:15 pm
Session VI
Chairs: Ulrike Köhl (Fraunhofer IZI / University Medicine Leipzig, Germany) & Katrin Mestermann (Fraunhofer IZI, Germany)
In vivo CAR T cells have reached the clinical stage
Keynote
Christian Buchholz (Paul-Ehrlich-Institut, Germany)
CAST: A translational platform to facilitate cell and gene therapy
Keynote
Mattias Carlsten (Karolinska Institutet, Sweden)
Keynote
Knut Steffensen (Karolinska Institutet, Sweden)
Allogeneic TCR-engineered NK cells as an off-the-shelf platform for intracellular antigen targeting in infection and cancer
Frederik Feigl (Fraunhofer IZI, Germany)
A next-generation ionizable lipid LNP platform for efficient in vivo CAR T cell generation across species through passive and active immune cell targeting strategies
Martin Rabel (Cytiva, Canada)